EG HPCP 03a
Alternative Names: EG-HPCP-03aLatest Information Update: 11 Aug 2023
At a glance
- Originator Evergreen Therapeutics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical COVID-19 pneumonia
Most Recent Events
- 28 Jul 2023 Evergreen Therapeutics withdrew a phase-II trial in COVID-19 pneumonia in China (IM) prior to enrolment (NCT04561180)
- 08 Oct 2020 Evergreen Therapeutics plans a phase II trial for COVID-19 pneumonia in China (IM, Injection) (NCT04561180)
- 23 Sep 2020 Preclinical trials in COVID-19 pneumonia in China (IM, Injection), prior to September 2020